Tumor biology in older breast cancer patients - What is the impact on survival stratified for guideline adherence? A retrospective multicentre cohort study of 5378 patients

被引:11
|
作者
Ebner, Florian [1 ]
van Ewijk, Reyn [2 ,3 ]
Woeckel, Achim [4 ]
Hancke, Katharina [1 ]
Schwentner, Lukas [1 ]
Fink, Visnja [1 ]
Kreienberg, Rolf [1 ]
Janni, Wolfgang [1 ]
Blettner, Maria [2 ]
机构
[1] Univ Ulm, Klin Frauenheilkunde & Geburtshilfe, D-89075 Ulm, Germany
[2] Johannes Gutenberg Univ Mainz, Univ Med, IMBEI, D-55131 Mainz, Germany
[3] Johannes Gutenberg Univ Mainz, Inst Wirtschaftswissensch, D-55128 Mainz, Germany
[4] Univ Wurzburg, Frauenklin & Poliklin, D-97080 Wurzburg, Germany
来源
BREAST | 2015年 / 24卷 / 03期
关键词
Breast cancer; Guideline; Survival; Older; Elderly; WOMEN; 80; YEARS; AGED; 70; ADJUVANT CHEMOTHERAPY; ELDERLY-WOMEN; RADIATION-THERAPY; STAGE; SURGERY; YOUNGER; DISCONTINUATION; CONSERVATION;
D O I
10.1016/j.breast.2015.02.029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The tumor biology of older breast cancer patients (oBCP) is usually less aggressive, however applied adjuvant treatment is often less potent resulting in an impaired disease free survival and overall survival in this group. This study tries to answer the following questions for the biological subtypes of oBCP (70+ y): (1) Is there a significant difference in the distribution of the biological subtypes of oBCP vs younger breast cancer patients (yBCP; 50-69 y)? (2) Which biological subtype has the highest rate of non-guideline-adherent-treatment (GL-) among oBCP? (3) Is a single GL- (i.e. radiotherapy/surgery/endocrine-therapy/chemotherapy) significantly associated with the survival outcome in each biological subgroup? Methods: Between 1992 and 2008 the BRENDA ('BRENDA' = quality of BREast caNcer care unDer evidence-bAsed guidelines) study group recorded medical data of 17 participating certified breast cancer centers in Germany. We performed a retrospective multi-center database analysis of 5632 patient records. Guideline-adherent-treatment (GL+) of oBCP(n = 1918) was compared to GL+ of yBCP(n = 3714). Results: OBCP were more likely to have hormone receptor positive (HR+) and HER2neu negative (HER2-) breast cancer (77.5% vs 74.5%). The rate of GL- was significantly different (p < 0.001) between the age groups and the biological subgroups (yBCP vs oBCP: 21.8% vs38.8% (HR+/HER2-); 30.6%vs49.7% (HR+/HER2-); 23.6%vs69.5% (HR+/HER2-); 31.4%vs67.8% (TNBC)). The survival parameters for HR+/HER2- and TNBC were significantly worse in case of GL- regarding chemotherapy, and if applicable endocrine therapy. A similar association only existed in HR+/HER2- tumors for GL- for radiotherapy and in HR+/HER2- tumors for chemotherapy. Conclusions: Beside the significantly different distribution of biological subtypes in the age groups there is an association between biological subtype, and GL- influencing survival parameters in oBCP. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:256 / 262
页数:7
相关论文
共 50 条
  • [1] Tumor biology in older breast cancer patients - what is the impact on survival stratified for guideline adherence? A retrospective multi-center cohort study of 5378 patients
    Ebner, Florian
    Hancke, Katherina
    Blettner, Maria
    Schwentnei, Lukas
    Woeckel, Achim
    Kreienberg, Rolf
    Janni, Wolfgang
    van Ewijk, Reyn
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2015, 36 : S101 - S101
  • [2] Impact of Guideline Therapy on the Survival of Patients with Primary Breast Cancer - Results of a Retrospective Cohort Study
    Giersiepen, Klaus
    [J]. ZEITSCHRIFT FUR EVIDENZ FORTBILDUNG UND QUALITAET IM GESUNDHEITSWESEN, 2011, 105 (09): : 687 - 688
  • [3] THE IMPACT OF GUIDELINE ADHERENCE ON SURVIVAL IN EARLY BREAST CANCER PATIENTS
    Mevius, A.
    Mueller, S.
    Wilke, T.
    Maywald, U.
    [J]. VALUE IN HEALTH, 2020, 23 : S482 - S482
  • [4] Comorbidity-dependent adherence to guidelines and survival in breast cancerIs there a role for guideline adherence in comorbid breast cancer patients? A retrospective cohort study with 2137 patients
    Wollschlaeger, Daniel
    Meng, Xiaoyu
    Woeckel, Achim
    Janni, Wolfgang
    Kreienberg, Rolf
    Blettner, Maria
    Schwentner, Lukas
    [J]. BREAST JOURNAL, 2018, 24 (02): : 120 - 127
  • [5] Adherence to Treatment Guidelines and Associated Survival in Older Patients with Prostate Cancer: A Prospective Multicentre Cohort Study
    Serrano, Adolfo Gonzalez
    Tapia, Claudia Martinez
    de la Taille, Alexandre
    Mongiat-Artus, Pierre
    Irani, Jacques
    Bex, Axel
    Paillaud, Elena
    Audureau, Etienne
    Barnay, Thomas
    Laurent, Marie
    Canoui-Poitrine, Florence
    [J]. CANCERS, 2021, 13 (18)
  • [6] Is Guideline Adherence the Key to Increased Survival in Patients with Breast Cancer?
    Hoffmann, Falk
    Andersohn, Frank
    [J]. ONCOLOGY, 2010, 79 (3-4) : 301 - 302
  • [7] Effects of guideline-compliant therapy on the survival of primary breast cancer patients with: Results of a retrospective cohort study
    Wolters, Regine
    Woeckel, Achim
    Wischnewsky, Manfred
    Kreienberg, Rolf
    [J]. ZEITSCHRIFT FUR EVIDENZ FORTBILDUNG UND QUALITAET IM GESUNDHEITSWESEN, 2011, 105 (06): : 468 - 475
  • [8] Aggressive Intrinsic Subtypes in Breast Cancer: A Predictor of Guideline Adherence in Older Patients With Breast Cancer?
    Ebner, Florian
    Hancke, Katharina
    Blettner, Maria
    Schwentner, Lukas
    Wockel, Achim
    Kreienberg, Rolf
    Janni, Wolfgang
    van Ewijk, Reyn
    [J]. CLINICAL BREAST CANCER, 2015, 15 (04) : E189 - E195
  • [9] Declined Guideline Adherence in Older Breast Cancer Patients: A Population-Based Study in The Netherlands
    Weggelaar, Ines
    Aben, Katja K.
    Warle, Michiel C.
    Strobbe, Luc J.
    van Spronsen, Dick Johan
    [J]. BREAST JOURNAL, 2011, 17 (03): : 239 - 245
  • [10] The impact of adjuvant radiotherapy on survival in primary breast caner: What is the role of guideline adherence in radiotherapy - A retrospective multi-center cohort study of 8935
    Woeckel, A.
    Wolters, R.
    Wiegel, T.
    Janni, W.
    Kreienberg, R.
    Wischnewsky, M.
    Schwentner, L.
    [J]. CANCER RESEARCH, 2013, 73